Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

MDxHealth SA Epigenetic Marker as Companion Diagnostic for Irinotecan based Therapy in Colorectal Cancer


Monday, 3 Jun 2013 02:02am EDT 

MDxHealth SA announced data showing that methylation of the Decoy Receptor 1 (DCR1) gene may help guide oncologists in selecting metastatic colorectal cancer (CRC) patients to receive irinotecan­based therapy. The data, presented on June 2nd at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA, showed that CRC patients with methylated DCR1 did not benefit from the addition of irinotecan to capecitabine therapy. Identification of DCR1 as a novel hypermethylated gene associated with a lack of benefit in adding irinotecan to capecitabine when treating metastatic colorectal cancer was performed in the pathology department of Prof. Gerrit Meijer (VUmc, Amsterdam) as part of the CTMM public-private partnership DeCoDe (Decrease Colorectal Cancer Death) project. The presence of DNA methylation for a selected panel of 22 genes was assessed on primary tumors of 185 patients with metastatic CRC treated with first­line capecitabine (CAP, n=90) or a combination of capecitabine and irinotecan (CAPIRI, n=95) in the phase 3 CAIRO trial. Methylation status of each gene was correlated to progression free survival (PFS) by treatment regimen. Genes for which methylation status was associated with response to irinotecan were validated in 166 patients treated with first­line CAP (n=78) or CAPIRI (n=88). In CAPIRI treated patients, DCR1 methylation was correlated to a shorter PFS compared to patients with unmethylated DCR1 (hazard ratio HR=0.4, p = 0.0009). 

Company Quote

4.365
-0.085 -1.91%
24 Dec 2014